Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-09-09 16:12:51 ET · period of report 2026-09-04 · accession 0001827584-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-09 16:12 | 2026-09-04 | TARS | Neervannan Seshadri | COO | S - Sale | $85.00 | -4,564 | 78.5K | -5% | -$387.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-04 | S | D | 4,564 | $85.00 | 78,532 | D | — | — | (F1) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |